Study wrapper · #940
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
Elmendorf AJ, Yousefian M, Kim IM, et al. Pharmacological research. 2026.
DOI: 10.1016/j.phrs.2025.108077PubMed: 41478576
ReviewMentions: Retatrutide
Editor's note
This IUPHAR review focuses on the mechanistic rationale for glucagon-receptor agonism in metabolic disease, with retatrutide cited as a leading triple agonist. The authors note that the evidence base is largely preclinical rodent data and that human confirmation remains limited. Valuable for mechanism context rather than clinical outcomes.
Plain-language abstract
A mechanistic review of how glucagon-receptor agonism, combined with GLP-1 and GIP agonism in agents like retatrutide, is being studied to increase energy expenditure for weight loss.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026